Press Release

Increasing Number of Cancer Cases Triggers the High Potent Active Pharmaceutical Ingredient Market

Date : Mar 10, 2023

Ameco Research Analyst imply that the global market for High Potent Active Pharmaceutical Ingredient (HPAPI) will raise at a CAGR of more than 8% throughout the forecast period, with market size of USD 21.5 Billion in 2020.

The intended function of an API, according to the FDA, is to provide pharmacological activity or another direct effect in the diagnosis, mitigation, treatment, cure, or prevention of disease, or to modify the structure or purpose of the body. Highly potent active pharmaceutical ingredients (HPAPIs) are chemicals that trigger a biological reaction in a very small amount of time. Cytotoxic chemicals and sex hormones like oestrogen are common examples of HPAPIs. Any molecule, however, can be highly potent if it produces a response at a modest dose. High potency (API), which are effective at significantly lower dosages than APIs, are a fast developing business, driven primarily by their value in cancer treatment and efficacy as antibody-drug conjugates (ADC). However, because HPAPIs generally have significant cytotoxicity in addition to high potency, measures to prevent cross-contamination are critical to a safe production process that protects staff, the environment, and patients.

Request for a sample of this premium research report @

The increasing incidences of cancer globally stimulates the HPAPI market

According to the GLOBOCAN and International Agency for Research on Cancer, there were an estimated 19.3 million cases of cancer in 2020. Due to demographic shifts, the worldwide cancer burden is anticipated to rise to 28.4 million cases in 2040, a 47 percent increase from 2020, with a bigger increase in transitional nations versus transitioned. Cancer is the biggest cause of death in the United States for individuals in their forties and fifties, and it may soon overtake heart disease as the leading cause of death overall, as the number of people detected with and dying from cancer continues to rise.

HPAPIs are pharmacologically active and highly potent molecules. They work on a very specific mechanism and are effective even at low daily therapeutic doses. Because HPAPIs can target specific disease cells, they are used in the development of very effective treatments. The rising number of cancer cases has a significant impact on cancer medicine sales around the world. The top 20 cancer treatments in the pharmaceutical industry, according to a study published in Nature Reviews, generate yearly sales of more than US$ 50 bn worldwide, with Roche's Avastin, Herceptin, and Rituxan coming in first with US$ 21 bn.

Even though the HPAPIs market is young and growing, pharmaceutical companies face significant challenges in upgrading their existing facilities, which are only capable of handling low- or medium-potency APIs. A large percentage of the budget is spent on specialized containment to protect employees and the environment against contamination. Aside from standard GMP production facilities, contract manufacturers are required to invest significantly in the building of new facilities specifically designed for HPAPI manufacturing, which can cost millions of dollars.

Furthermore, growing opportunities from emerging economies are expected to propel the demand in the coming years. The active pharmaceutical ingredient market has a bright future, with prospects in cancer, cardiology, pulmonology, orthopedics, ophthalmology, neurology, nutrition, and anti-inflammatory therapeutic areas. Emerging Trends in the developing countries' business include an increase in the adoption of advanced technology in API manufacture, an increase in demand for high potency APIs, and an increase in the use of binder for the development of peroxide sensitive APIs. In addition, favorable support from the government is also likely to create growth prospects for the market in the future. The rise of the HPAPI market is being fueled by several demographic factors. These include rapidly changing population dynamics, such as population expansion and population aging at the same time. In addition, as a result of lifestyle changes, non-contagious chronic diseases and disorders such as cancer, cardiovascular disease, type-2 diabetes, and obesity have grown.

Global High Potent Active Pharmaceutical Ingredient (HPAPI) Market Classification

The high potent active pharmaceutical ingredient (HPAPI) market is divided into five categories product type, drug type, manufacturer type, application, and regions. The product type segment can be categorized into biotech and synthetic. Among them, the synthetic segment accumulated the prime market share in 2020. Generic and innovative are the bifurcation of drug-type segments. The innovative drug type segment acquired the maximum amount of share in 2020. On the basis of manufacturer type, the segmentation is given as in-house and outsourced. The analysis says that in 2020 the in-house segment gathered a significant amount of share. Hormonal disorders, glaucoma, oncology, and others are covered under the application segment. Among them, the oncology segment recorded the maximum share in 2020.

Regional Stance

North America, Latin America, Asia-Pacific, Europe, and the Middle East & Africa (MEA) are the regional categorization of the global high potent active pharmaceutical ingredient (HPAPI) market. North America accounted for the maximum share in 2020. This might be linked to the region's growing demand for HPAPIs, as well as the existence of important manufacturers and superior technological infrastructure. The Asia-Pacific area, on the other hand, is expected to increase at the quickest rate between 2021 and 2028. The expanding senior population, high prevalence of chronic and lifestyle disorders, and increase in disposable income are all contributing to the region's rapid growth.

Major Players

The top players offered in the report include BASF SE, Cipla Inc., Dr. Reddy’s Laboratories Ltd., Pfizer, Inc., Merck & Co., Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., and Cambrex.

To receive personalized service, please share your research needs here@

Buy this premium research report -

Contact Us:

Mr. Richard

Ameco Research

USA: +1 347 474 3864

India: +91 8983225533